Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New risk score could help stomach cancer patients avoid unnecessary surgery

NCT ID NCT06339307

Knowledge-focused Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a risk scoring model that predicts whether stomach cancer has spread to nearby lymph nodes before surgery. Researchers looked at data from 120 patients who had their stomach cancer removed. The goal was to see if the model could help doctors make better treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the model proves accurate, it could help doctors better plan surgery and avoid unnecessary procedures for gastric cancer patients.
What could go wrong
This is a small, completed validation study, not a treatment trial. The model may not be accurate enough for all patients or may not change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

120 people

The number who actually took part.

Started

Feb 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who were diagnosed with gastric cancer pathologically and underwent curative gastrectomy.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Primary gastric adenocarcinoma; 2. Curative surgery (with R0 resection, excluding palliative surgery and cases with distant metastasis). Exclusion Criteria: 1. Patients with autoimmune diseases, inflammation, or hematological disorders; 2. Patients with a history of or concurrent other cancers; 3. Presence of active infection and inflammation (based on WBC count, patients with count of 10×10\^9 or higher should be evaluated through medical record examination for the presence of infection); 4. Active bleeding (as determined by endoscopic ultrasound and HGB ≤ 90); 5. Post neoadjuvant radiotherapy or chemotherapy; 6. History of blood transfusion, corticosteroid use, or leukocyte-stimulating medications within the past month prior to blood draw; 7. Incomplete clinical and pathological data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm Lymphatic Metastasis metastatic malignant neoplasm in the lymph nodes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer Lymph node metastasis Predictive cancer model

Contacts and locations

Locations

  • Cancer Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.